10X Genomics Inc at JPMorgan Healthcare Conference Transcript
Hi, everyone. This is Rachel Vatnsdal, from the Life Science Tools and Diagnostics team with JPMorgan. Thank you so much for joining me today. I've got 10x Genomics on stage. I'm first going to introduce Serge, CEO of 10x. He is going to start off with a presentation around 20 minutes, give or take, and then I'll shift to Q&A. If anyone in the room has questions, please feel free to either submit them via the app or you can pin me directly.
Thank you. Really great to be back here. So before we begin, I want to point out our safe harbor statement on Slide 2 and invite you to visit our website for additional disclosures regarding forward-looking statements made today.
So 2023, we had another strong year, finishing with $619 million in revenue, representing 20% growth from a year before. We had big increases in customer publications in intellectual property and in our installed base of instruments. In
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |